Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jazz Pharmaceuticals plc Director's Dealing 2012

Jan 13, 2012

30751_dirs_2012-01-13_39eaf336-7bf9-4f31-889e-40a90563373f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JAZZ PHARMACEUTICALS INC (JAZZ)
CIK: 0001232524
Period of Report: 2012-01-11

Reporting Person: MICHELSON MICHAEL W (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-01-11 Common Stock M 12500 $8.23 Acquired 12500 Direct
2012-01-11 Common Stock F 2116 $48.60 Disposed 10384 Direct
2012-01-11 Common Stock M 12500 $34.99 Acquired 22884 Direct
2012-01-11 Common Stock F 8999 $48.60 Disposed 13885 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-01-11 Option (right to buy) $8.23 M 12500 Disposed 2020-08-25 Common Stock (12500) Direct
2012-01-11 Option (right to buy) $34.99 M 12500 Disposed 2021-11-04 Common Stock (12500) Direct

Footnotes

F1: Represents shares withheld by the Issuer for cashless exercise of nonstatutory stock options solely to cover exercise price.

F2: The Reporting Person is a member of the Issuer's board of directors and is an executive of Kohlberg Kravis Roberts & Co. L.P. and/or one or more of its affiliates. The Reporting Person disclaims beneficial ownership of any securities beneficially owned by affiliates of Kohlberg Kravis Roberts & Co. L.P., except to the extent of his pecuniary interest therein.

F3: This nonstatutory stock option vested in 12 equal monthly installments from August 15, 2010.

F4: This nonstatutory stock option has a vesting schedule of 100% vesting in 12 equal monthly installments from August 15, 2011.

F5: On October 24, 2011, the Board of Directors of the Issuer approved the full vesting of unvested nonstatutory stock options held by the Issuer's officers and non-employee directors, including the Reporting Person. Such vesting acceleration became effective on December 13, 2011.